Understanding Variations in Relative Effectiveness : A Health Production Approach by Towse, Adrian et al.
	



	
					
	
	

	
				
 


!∀!#

!∃%	!&∋	!(!&
!∀
)

%    ∗   +∗,+−∗− ./!0%∗0
!	!&	∗12!#
%!0	
	
!
&3!45)+ 6./	%7	
	8	∀
9	0
	
∀
:		
#



%5∀;	9	
(:<<4 +..∗.+−
	

	
	=	

				

International Journal of Technology Assessment in Health Care, 31:6 (2015), Page 1 of 8.
c© Cambridge University Press 2016. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
doi:10.1017/S0266462315000719
UNDERSTANDING VARIATIONS IN RELATIVE
EFFECTIVENESS: A HEALTH PRODUCTION
APPROACH
Adrian Towse
Office of Health Economics
atowse@ohe.org
Bengt Jonsson
Stockholm School of Economics
Clare McGrath
AstraZeneca
Anne Mason
University of York
Ruth Puig-Peiro
Servei Catala` de la Salut (CatSalut)
Jorge Mestre-Ferrandiz, Michele Pistollato, Nancy Devlin
Office of Health Economics
Background: Relative effectiveness has become a key concern of health policy. In Europe, this is because of the need for early information to guide reimbursement and funding
decisions about new medical technologies. However, ways that effectiveness (does it work?) and efficacy (can it work?) might differ across health systems are poorly understood.
Methods: This study proposes an analytical framework, drawing on production function theory, to systematically identify and quantify the determinants of relative effectiveness and
sources of variation between populations and healthcare systems. We consider how methods such as stochastic frontier analysis and data envelopment analysis using a Malmquist
productivity index could in principle be used to generate evidence on, and improve understanding about, the sources of variation in relative effectiveness between countries and over
time.
Results: Better evidence on factors driving relative effectiveness could: inform decisions on how to best use a new technology to maximum effectiveness; establish the need if any for
follow-up post-launch studies, and provide evidence of the impact of new health technologies on outcomes in different healthcare systems.
Conclusions: The health production function approach for assessment of relative effectiveness is complementary to traditional experimental and observational studies, focusing on
identifying, collecting, and analyzing data at the national level, enabling comparisons to take place. There is a strong case for exploring the use of this approach to better understand
the impact of new medicines and devices for improvements in health outcomes.
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Relative, or comparative, effectiveness has become a key health
policy concern. Payers are increasingly interested in assessing
the relative effectiveness of new healthcare technologies rela-
tive to standard care or other designated comparators (1). This
reflects growing recognition of the need to understand how effi-
cacy demonstrated in a randomized controlled trial (RCT) will
translate into added benefit in routine clinical use in different
healthcare settings. Relative effectiveness evidence is also im-
portant when assessing whether results in one jurisdiction can
be applied elsewhere. Regulators want to use it in post-launch
benefit risk assessments (2). In the case of the anti-obesity
drug rimonabant, for example, such an assessment suggested
both that relative effectiveness was poorer than relative efficacy
and safety risks were higher than expected. The product was
Research funding was received from Pfizer. We thank three anonymous referees for their
constructive comments. We are also grateful to Rikard Althin for comments on the Malmquist
Index. All remaining errors and omissions are the responsibility of the authors.
subsequently withdrawn by the European Medicines Agency
(EMA) (3).
Relative effectiveness can be defined as “the extent to which
an intervention does more good than harm compared with one
or more alternative interventions under the usual circumstances
of healthcare practice” (4). This contrasts with relative efficacy,
which is a comparison “under ideal circumstances,” that is, “un-
der clinical trial conditions” (5). Comparative effectiveness is
very similar to relative effectiveness, and is defined as “com-
paring health outcomes and the clinical effectiveness, risks, and
benefits of two or more medical treatments, services, and items”
(6) which for Garber and Sox means “real world settings” (7).
We focus on the European Union (EU) to explore the translation
of relative efficacy into relative effectiveness in recognition of
current efforts to develop EU-level approaches to assessment.
There appears to be a general view that relative efficacy of
most therapies will be the same across Europe in most circum-
stances, although very few studies have tested that assumption
(8). In the RE-LY trial, the relative efficacy of a new oral antico-
agulant varied between countries even under RCT conditions,
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depending on the efficiency of warfarin management (9). Thus,
even relative efficacy can differ between countries when health-
care practice varies.
How relative effectiveness might differ across health sys-
tems within the EU is poorly understood. Yet variations in rela-
tive effectiveness have implications for: (i) The extent to which
national and regional pricing and reimbursement (P&R) deci-
sions vary, and why. This will depend on whether decisions
about patient access to medicines depend on considerations of
relative effectiveness and, if so, the extent to which relative ef-
ficacy is accepted as a proxy for it. (ii) The desire to assess
benefit–risk by the EMA beyond launch into the “product life
cycle” in which expected benefits are compared with expected
risks, based on evidence from actual use (10). (iii) The work of
the European network for Health Technology Assessment (EU-
netHTA) in particular Work Package 5 (WP5), to standardize
methods and data requirements for relative effectiveness assess-
ments across the Member States, including the applicability of
evidence from one setting to another (11), following the recom-
mendation of the High Level Pharmaceutical Forum in 2008.
(iv) The EU drive to increase cross border health care in Europe:
the implication is that citizens should obtain same health out-
comes regardless of the country where they obtain a treatment.
(v) The actions health systems can take to be sustainable and
meet health needs in the face of economic downturn (12). In the
United States, the purposes of conducting comparative effec-
tiveness research include providing both the basis to improve
care quality and to enable savings (13).
Health technology industries face a paradigm shift if they
are to be paid and regulated on the basis of “does it work?”
(effectiveness) instead of “can it work?” (efficacy) (14). Indus-
try remuneration and regulatory benefit–risk assessment would
also depend on the actual capacity, competence, or other abil-
ity of the healthcare system to provide access to and otherwise
appropriately deliver the drug, that is, the effectiveness of the
system, as well as the potential effectiveness of the drug. This
has two consequences. First, there is an increased demand for
studies to identify local impact. In the extreme, if a company
has to plan to conduct different relative effectiveness studies
for twenty-eight EU Member States post launch, the implica-
tions for development costs may be substantial, even if done in
collaboration with healthcare systems. Second, evidence of rel-
ative effectiveness in routine use will need to be integrated into a
range of decisions: not only decisions on reimbursement or reg-
ulatory status, but also decisions about any required changes to
current care practices needed if the benefits of new technologies
are to be optimized.
METHODS
This study focuses on how we can identify whether and to
what extent relative effectiveness differs across EU healthcare
systems, and what data and methods are needed to study the
impact of changes over time when new treatment options are
introduced. We undertook a brief scoping review to identify
approaches to measure relative effectiveness. We focused on
literature reviews and empirical studies that distinguished be-
tween efficacy and effectiveness, that is, outcomes in clinical
practice. We then explored the potential relevance of an analyt-
ical framework drawing on production function theory to con-
sider how certain sets of inputs and processes yield specified
outcomes. This approach can, in principle, provide a systematic
way of identifying and quantifying the determinants of rela-
tive effectiveness, and sources of variation between populations
and healthcare systems. We set out the elements of a multilevel
model in this study. In an accompanying article (15), we use
this model to categorize evidence on breast cancer to illustrate
potential differences in the relative effectiveness of a new drug
entering the market.
The production function approach is complementary to tra-
ditional experimental and observational studies, and focuses on
identifying, collecting, and analyzing data at the national level
for assessment of relative effectiveness. Our approach consisted
of four steps. First, we set out an analytical framework. The
health production function approach uses health as the output
of interest. This reflects the EU Directive on cross border care
which forms the basis for the coordination of health technol-
ogy assessment (HTA) and relative effectiveness assessment in
Europe (16). Relative effectiveness is the basis for assessing
therapeutic added value and cost-effectiveness at the national
level. What determines value is the absolute difference in ef-
fectiveness, which translates for example into the number of
QALYs gained. Second, we classify inputs (or “factors”) into
three main levels: patient, provider, and the healthcare envi-
ronment or system. The relative effectiveness of a drug is the
additional net output (health) achieved by adding a new drug
to usual care or substituting it for another treatment. Third, the
health production function provides an approach to organize the
data and an analytical framework to examine the differences in
relative effectiveness across jurisdictions. We briefly outline the
types of model that might be appropriate and consider its role
in relation to the increasing demand for observational studies
of the impact of the use of drugs in practice. Lastly, we consider
the policy implications of our analysis.
RESULTS
Understanding the Reasons for Differences in Relative Effectiveness
Eichler et al. (1) set out the methodological options and chal-
lenges in measuring relative efficacy. Their subsequent com-
prehensive review (5) identified two reasons for an “efficacy-
effectiveness gap”: biological (including genetics, age, sex,
co-morbidity and baseline severity of disease) and behav-
ioral (e.g., variation in adherence to the treatment regimen).
Economists would add that any understanding of a potential
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“efficacy-effectiveness gap” requires translating trial outcomes
into long-term health outcomes. However other factors will
also play a role, notably the health system. For example, the
health system and the environment impact on disease severity
and co-morbidity. Adherence is not only behavioral, but also
depends on the organization and resources used for manag-
ing adherence, and thus the efficiency of the healthcare sys-
tem. The selection of patients for treatment and the manage-
ment of patients over time will depend on incentives, organi-
zation and resources in the healthcare system. These elements
may differ across jurisdictions and will impact on long-term
outcomes.
Estimating Relative Effectiveness: Empirical Methods
Currently relative effectiveness, as opposed to relative efficacy,
is treated in the literature and assessed by HTA and reim-
bursement agencies in one of three ways: (i) It is assumed
to be the same as relative efficacy, and any potential “efficacy-
effectiveness gap” is ignored, that is, modelling is based on
clinical trial data. (ii) It is estimated using decision analytical
modelling. However, this technique is typically used to project
longer term health outcomes from short term or intermediate
efficacy measures, or to make indirect comparisons, rather than
to model the impact of the health system on the translation of
the efficacy of a technology into outcomes in routine care. An
intermediate case is when the relative risk reduction from a trial
is applied to the absolute risk level for different groups of pa-
tients in different countries (17). However, this approach does
not take into account other factors that may influence relative
effectiveness, for example differences in adherence between
countries. (iii) Observational studies or pragmatic clinical trials
are proposed as methods to explore outcomes in routine clini-
cal practice within a healthcare system (17–19). The number of
observational studies being undertaken within health systems is
increasing, but they can be time consuming and expensive un-
less relevant data are already routinely captured by a healthcare
system. Analysis can be complex and results open to differing
interpretations, although methods to tackle confounding and
other issues are improving. Pragmatic trials also can be time
consuming and expensive unless infrastructure investment is
put in place and recruitment streamlined.
None of these approaches are routinely used to detect and
explain differences in relative effectiveness across health sys-
tems. A review of the literature (8) found no observational
studies investigating variations in relative effectiveness across
Member States, although there were safety studies and studies
comparing other aspects of care across several Member States. It
is, therefore, not possible to address the question of differences
in relative effectiveness on the basis of current evidence.
One route forward is for more observational studies or prag-
matic clinical trials to be conducted across Member States.
Given the cost and complexity of conducting them, however, it
would make sense to explore another approach which can use
existing data, and could be used to help identify whether differ-
ences in relative effectiveness were likely to be of an order to
merit further study.
The Conceptual Framework: A Health Production Function Model of the
Determinants of Relative Effectiveness
The relative effectiveness of a new technology is likely to depend
on how it is combined with other health inputs, and a range of
other variables that influence the overall relationship between
inputs and health outcomes in the underlying “health production
function.”
Assuming the comparator treatment is one of the inputs in
the initial health production function, then relative effectiveness
is the change that results when the new treatment is introduced
relative to that obtained from the existing (or usual) treatment
(and other inputs). In this context, “usual care” in the health
system will be a key determinant of the relative effectiveness of
any new treatment. The underlying research questions are: if a
medicine for, say, breast cancer is granted Market Authorization
by the EMA, indicating that the new technology is available in
all EU countries, do we expect that its relative effectiveness will
be different across them? If so, why?
One way to investigate influences on relative effectiveness
is to treat this analytically as a multilevel model, separating the
different levels of influence. Influences may operate on one or
more of three main levels: patient, provider, and the healthcare
environment and system (see Table 1): (i) “Individual” patient
level factors refer to the characteristics of the patients being
treated, including their demographic, genetic, and clinical char-
acteristics. Not only may the patient mix gaining access to the
technology differ but underlying population health may also dif-
fer between health systems. The same technology in the same
setting may, therefore, produce different health effects depend-
ing on patient characteristics. Even if relative efficacy is the
same across two health systems, if baseline risk differs then
size of the absolute incremental effect measured by relative ef-
fectiveness may differ. (ii) The characteristics of the providers.
The same technology may produce different health effects on
patients with similar characteristics depending on how it is used
and combined with other technologies in clinical practice (e.g.,
screening policy, or treatment setting; see Table 1). Clinical
practice may vary in other ways that influence treatment out-
comes (both from new technologies and comparators) for ex-
ample due to economic and other incentives for providers. (iii)
Healthcare environment and system factors. The availability or
otherwise of technologies within the healthcare system and how
technologies are used (and hence the health effects on patients)
(i.e., “comparators” in Table 1) is often driven by P&R policies
and clinical guidelines from regional or national decision mak-
ers. Waiting times for referral and then access to specialist care
also vary between (and within) countries.
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Table 1. Overview of Factors That May Influence the Relative Effectiveness of a Medicine or Other Technology
Influence level Category Variables
Individual / patient level factors Demographic characteristics Age; gender; socioeconomic status; education; insurance status;
employment status; lifestyle factors (e.g., smoking status)
Clinical characteristics Disease severity, including disease stage at diagnosis; co-morbidity;
procedures received; general health and life expectancy; genetic type
Other characteristics Compliance /concordance; health literacy/awareness
Provider level factors Provider characteristics Specialization; private/public status; teaching status; clinical practice (e.g.
hospital policy on use of off-label drugs); capital / labor availability (e.g.
physician skills, CT scanner); patient selection.
Environment/health care system level factors Population health Lifestyles, mortality rates, life expectancy, disease prevalence; valuation of
outcomes (e.g. EQ-5D values)
National /regional guidelines / regulations Clinical guidelines; national service frameworks/national plans; legal
framework (e.g. funding for some drugs /services may be mandatory)
Service delivery and organization Screening, treatment settings, provision of palliative care
Access issues (local regional/national) Pricing and reimbursement policies ; insurance and co-payment policies;
waiting time targets; comparator drug(s) available
Economy GDP; % GDP spent on health care; % private funding for health care
Some determinants of outcome operate and interact at sev-
eral levels. Five-year survival rate for breast cancer may dif-
fer across countries due (in part) to differences in all-cause
mortality rates. These may be due to individual-level effects
(e.g., smoking status), to environmental effects (e.g., taxes on
cigarettes), or to health system public health measures restrict-
ing smoking. The key is to identify factors driving outcomes
and ensure they are included, but only once. In this example,
the variable for smoking would be most appropriately classi-
fied and included in the analysis as an individual level effect.
In the accompanying article (15), we provide an overview of
factors affecting breast cancer outcomes identified from a lit-
erature review, grouping them according to the multilevel ap-
proach: “individual level,” “provider level,” and “environment
and healthcare system level” set out in Table 1. The results are
set out in Table 2 of Puig-Peiro et al. (15).
The Malmquist DEA Model for Measuring Relative Effectiveness
The theory and methods for estimating health production func-
tions have developed rapidly over the past 2 decades. Impor-
tant contributions include the development of econometric ap-
proaches such as the stochastic frontier approach (20;21), and
also data envelopment analysis (DEA) (22;23), including the
use of Malmquist indexes which allow use of multiple input,
multiple output models without prices. The latter is particularly
important in a European healthcare perspective, where prices
vary between countries, and often are not possible to observe
and calculate in public healthcare systems. In addition, for some
inputs to the health production function, such as an individual’s
time and effort used for prevention and treatment prices are not
directly observable, as is also the case for the output health.
Using index numbers that include prices for measurement of
changes in total factor productivity, that is, relative effective-
ness is not an option.
A further advantage of the Malmquist approach is that, once
the production technology is estimated, either as a production
frontier or its dual the cost frontier, one can decompose the
change in two component parts: efficiency change and techni-
cal change. The methodology proposed by Fa¨re et al. (1994)
(24) uses DEA to calculate distance functions to produce the
Malmquist total factor productivity index, and then decomposes
this into technical and efficiency components respectively. This
decomposition is important because the change in relative ef-
fectiveness in a given countries is made up by a combination
of changes in the frontier, and how the country is moving in
relation to the frontier.
Figure 1 illustrates how a Malmquist DEA model could
help identify and explain potential cross-country variations in
the relative effectiveness of the introduction of a new treatment
for breast cancer treatment. It can be used to study and de-
compose the productivity changes both in terms of technical
change (best practice change, shown by a shift in the frontier)
and technical efficiency change (countries moving closer to the
frontier), that is, to understand how the introduction of a new
technology changes outcomes, and hence to establish its relative
effectiveness. This is essential for the design of policies aimed
at improving relative effectiveness.
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Figure 1. Illustration of the Malmquist Index applied to the identification of possible variations in the relative effectiveness of breast cancer treatments.
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For illustrative purposes, we assume just two inputs, but
in practice the estimation of these models can include multiple
inputs and patient attributes such as those set out in Table 1
that will impact on the patient outcomes. The horizontal axis
measures the number of “physician visits” as a proxy for the
intensity of monitoring and nondrug treatment, and the vertical
axis measures the number of doses of “drugs” as a proxy for
the intensity of drug treatment. We could also have used for
example the share of visits to a specialist on the horizontal
axis and an index of “vintage,” that is, year of introduction, for
drugs. For illustration, we show the various combinations of the
two variables that yield an 85 percent 5-year survival rate. The
Production Frontier in Figure 1 is data-driven: it is the envelope
of the most efficient data points observed from all countries in
the group. We compare the average performance of two of the
countries, A and B.
In period t, before the introduction of the new drug, effi-
ciency is not the same in the two countries: eA is closer to the
production frontier in period t than is eB. They use different
combinations of input factors, which may reflect differences in
relative prices between drugs and physician visits in the two
countries. The distance function 0c/0e represents the technical
inefficiency in country A and B respectively in period t, that
is, how much the use of drugs and visits could have been re-
duced if they had applied the best practice use suggested by the
production frontier at period t.
When a new drug or procedure is introduced in period t+1,
the production frontier shifts inward, indicating an improvement
in technical efficiency to produce the same level of health out-
come with fewer of each of the inputs. The frontier may not
change by the same proportion for both countries suggesting
that one country may increase its efficiency in a larger propor-
tion than the other after the introduction of the new drug.
The distance functions 0a/0f shows the new degree of ineffi-
ciency, that is, actual performance compared with best practice
on the radial from the origin for the two countries, respectively.
For each observation, the change from period t to t+1 in
efficiency can be computed as the ratio between the two distance
functions, and the technical change as the geometric mean of the
product of two ratios. These are defined in the key to Figure 1.
The total productivity change, or change in relative effective-
ness is the product of the two ratios. All observations can be
aggregated to an overall productivity change, using the geomet-
ric mean.
The optimal mix of drugs and physician visits that would
occur once the new drug was available along the production
frontier in period t+1 depends on their relative prices and can
be studied separately.
We show, in Online Supplementary File 1, the potential use
of this approach with a very simple calculation and illustration
of the technical efficiency with which combinations of breast
cancer screening and treatment with trastuzumab are used in
seven European countries.
Strengths and Weaknesses of the Approach
Using such an approach to empirically identify and explain
differences in relative effectiveness may encounter some chal-
lenges in practice. For example, it would require data on all
relevant factors to be available in a manner that facilitates cross-
country comparisons. Furthermore, depending on the specific
factors identified as relevant to understanding relative effective-
ness in a specific disease area, relationships between explana-
tory variables (e.g., adherence may depend on socioeconomic
status) can confound identification of their relationship to out-
comes. However, such challenges are common to many studies
and do not preclude useful and valuable research being under-
taken.
Valid and reliable price data for (non-drug) inputs and out-
puts are generally not available, so techniques to estimate cross-
and time-series variations in the relationship between inputs and
outputs without price data, such as the approach illustrated in
Figure 1, are an important step forward. They have been ex-
tensively used to understand the relative efficiency of providers
(usually hospitals) within a single healthcare system and to com-
pare the performance of healthcare systems; see Hollingsworth
and Wildman (25), Greene (26), and the EUROHOPE project
(27). Jacobs et al. (28) and Coelli et al. (29) provide a compre-
hensive review of the main econometric approaches for mod-
elling health production functions.
Questions for the decision makers, based on such an anal-
ysis, should include: (i) whether a country can get closer to
best practice and improve relative effectiveness; (ii) whether
the likelihood of gaps between relative efficacy and relative ef-
fectiveness mean that post-launch studies are required; and (iii)
whether potential differences between countries A and B mean
that separate post-launch studies are needed in each.
We are not proposing econometric and economic modeling
as an alternative to a prospective observational study or prag-
matic trial to understand differences across healthcare systems
in the relative effectiveness of a technology. Rather, we see this
analytical tool as complementary: one that can use existing data
(including data already available from post-launch studies) to
explore the extent to which the performance of the same tech-
nology differs, or might be expected to differ, across settings as
a result of differences in populations and healthcare systems.
Policy Implications
There are prima facie reasons why we might expect some con-
vergence in relative effectiveness across the EU over time: the
diffusion of medical technology is becoming global and there
is a flow of information about best practice. It is also possible
to observe some convergence of healthcare systems in terms
of financing, organization, and performance. Yet our findings
suggest it is reasonable at the moment to expect meaningful
and persistent variations in relative effectiveness between and
within countries. Although the literature indicates that current
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understanding of what might be important is limited, each case
is likely to be driven by a few key factors. The health produc-
tion function is a tool for identifying these at an early stage and
making predictions of their likely quantitative impact. However,
it can also serve as a basis for targeting observational studies
and pragmatic clinical trials post launch, to test predictions and
gain further insight into how to best make use of the new tech-
nology, including the potential advantages and disadvantages
of using coverage with evidence development and risk sharing
arrangements to assess and reward relative performance.
There are four broad policy implications from our analysis.
First, at a time when we are seeing that countries increasingly
look at P&R decisions and HTA assessments in other coun-
tries, the debate around the transferability of relative effective-
ness evidence for P&R decisions could be better informed by
an understanding of what factors in a healthcare system are
likely in practice to impact on the incremental performance of a
technology.
Second, the increasing demand for post-launch studies to
address uncertainty about relative effectiveness of drugs needs
to be put in the context of such an understanding. Studies are
expensive and complex and unnecessary duplication of effort
could waste time and resources and delay patient access to ef-
fective treatments. A collaborative approach between industry
and governments (and in the EU across the twenty-eight Mem-
ber States) is required to: (i) Limit the number of extra studies.
An improved understanding of the drivers of relative effec-
tiveness can help prioritize these studies. They can be limited
to those needed to explore key expected differences between
health systems that could impact patient outcomes. (ii) Collect
and provide access to necessary data on the relevant contextual
factors. At present, access to routine data (for example from
registers) is often restricted. In Sweden, a public inquiry de-
scribed the registers as “a gold mine” for collecting evidence to
improve health care and health. Such registers are, however, of-
ten oriented to answering specific clinical questions and need to
be augmented with a wider set of relevant factors and outcomes
for the analysis of relative effectiveness.
Third, where differences in relative effectiveness reflect
variation in the efficiency of healthcare systems, good prac-
tice can be identified and shared. Decision makers in poorly
performing health systems, who are responsible for the pro-
curement of new technologies and for managing healthcare
providers, can learn from good practice elsewhere. Relative ef-
fectiveness is the outcome of an interaction between a technol-
ogy, patients, and the health system (including the providers).
The role of the latter and how to improve efficiency is often
missing from debates such as that about developing an EU
assessment of relative effectiveness. Failure to improve health
system performance risks wasted resources or poorer health
outcomes.
Fourth, if industry remuneration and regulatory benefit–risk
assessment increasingly depend on the actual effectiveness of
the healthcare system in using a drug, as opposed to relative ef-
ficacy at launch, then we may see an increasing use of “pay for
performance” and risk sharing agreements. Such agreements
are, in effect, seeking to estimate the health production function
and link payment in some way to the use or outcome. Without
an understanding of the contextual factors, there is a danger
of companies taking the “risk” for factors that are really the
responsibility of the health system and vice versa. The poten-
tial for using post-launch follow-up studies to reduce the time
and cost of drug development before market authorization in
some areas (cancer being an example where fast access is im-
portant and risks can be managed) needs to be informed by an
understanding of the key factors driving relative effectiveness.
CONCLUSIONS
We conclude that the step from relative efficacy to relative ef-
fectiveness can be substantial and is likely to vary across health
systems. Relative efficacy is a function of the attributes of the
technology and target patient population. Relative effective-
ness additionally depends on the performance of the healthcare
delivery system and wider environmental factors. The poten-
tial for differences in relative effectiveness across EU Member
State health systems gives rise to several public policy issues.
The health production function approach is complementary to
traditional experimental and observational studies, focusing on
identifying, collecting, and analyzing data at the national level
for assessment of relative effectiveness, enabling comparisons
to take place. There is a strong case for exploring the use of
this approach to enable the differences to be estimated and ad-
dressed and any requirements for post-launch observational or
experimental studies to be targeted.
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